Compare ELVN & USAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELVN | USAS |
|---|---|---|
| Founded | 2016 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Mining |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2020 | N/A |
| Metric | ELVN | USAS |
|---|---|---|
| Price | $21.65 | $4.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $41.20 | $4.08 |
| AVG Volume (30 Days) | 511.8K | ★ 3.3M |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $104,867,000.00 |
| Revenue This Year | N/A | $22.65 |
| Revenue Next Year | N/A | $69.86 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.30 | $0.87 |
| 52 Week High | $25.96 | $5.12 |
| Indicator | ELVN | USAS |
|---|---|---|
| Relative Strength Index (RSI) | 54.55 | 61.56 |
| Support Level | $19.58 | $4.25 |
| Resistance Level | $21.79 | $4.65 |
| Average True Range (ATR) | 1.19 | 0.26 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 57.56 | 84.11 |
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Americas Gold And Silver Corp is a mining company engaged in the acquisition, exploration, development, and production of precious metals mineral properties in Mexico and the United States. The company's primary operating assets, which are also its reporting segments, are the Cosala operations, the Galena Complex, and Relief Canyon. It also holds interests in the San Felipe Development Project located in Sonora, Mexico. The Cosala operations segment, which derives maximum revenue, operates in Mexico, while the Galena Complex and Relief Canyon segments operate in the United States.